BUSINESS● LOW2h ago · Sep 17, 2026, 3:21 PM
Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial
Yahoo Finance · global
Novartis and Ionis's late-stage trial for a cholesterol drug failed to meet expectations. This represents a setback for pharmaceutical companies in drug development.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESSnowHow Afreximbank's PAPSS aims to connect Africa to the rest of the worldJeune AfriqueBUSINESS20m agoChelsea ambition ‘very clear’ after end of Boehly era – Xabi AlonsoVanguard Nigeria